TY - JOUR
T1 - Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – The 2020 COVID-19 pandemic
T2 - A statement from the EAACI-section on pediatrics
AU - Brough, Helen A.
AU - Kalayci, Omer
AU - Sediva, Anna
AU - Untersmayr, Eva
AU - Munblit, Daniel
AU - Rodriguez del Rio, Pablo
AU - Vazquez-Ortiz, Marta
AU - Arasi, Stefania
AU - Alvaro-Lozano, Montserrat
AU - Tsabouri, Sophia
AU - Galli, Elena
AU - Beken, Burcin
AU - Eigenmann, Philippe A.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and healthcare providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, and bronchodilators, increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic, and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence.
AB - While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and healthcare providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, and bronchodilators, increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic, and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence.
KW - allergy
KW - asthma
KW - biologics
KW - children
KW - coronavirus
KW - corticosteroids
KW - COVID-19
KW - immunodeficiency
KW - SARS-CoV-2
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85084360830&partnerID=8YFLogxK
U2 - 10.1111/pai.13262
DO - 10.1111/pai.13262
M3 - Review article
C2 - 32319129
AN - SCOPUS:85084360830
SN - 0905-6157
VL - 31
SP - 442
EP - 448
JO - Pediatric Allergy and Immunology
JF - Pediatric Allergy and Immunology
IS - 5
ER -